Felzartamab not checked

Biogen · MOR202 · TJ202

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
8 active
16 in total · 5 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“Participants will receive felzartamab by intravenous infusion.”In the company’s words, NCT06685757 on ClinicalTrials.gov
Tested for
Antibody-mediated Rejection (2 trials), Microvascular Inflammation (2 trials), Immunoglobulin A Nephropathy (IgAN), Primary Membranous Nephropathy, Graves' Disease, Immunoglobulin A Nephropathy, Generalized Myasthenia Gravis
Main trialPhase 3
“In this study, researchers will learn more about the use of felzartamab in kidney transplant patients who have antibody-mediated rejection, also known as AMR. Kidney transplants can save lives for people with kidney failure. But even after a successful transplant, the body's immune system can sometimes attack the new kidney. Antibody-mediated rejection (AMR) is when a person's immune system attacks a transplanted organ, like a new kidney. In the person receiving the transplant, their immune system creates specific antibodies. Antibodies are proteins that help the body fight infections. In…”In the company’s words, NCT06685757 on ClinicalTrials.gov
Other names
MOR202 · TJ202 · BIIB148 · MOR03087 · HIB202

Other drugs for Immunoglobulin A Nephropathy (IgAN)

All 39 drugs for Immunoglobulin A Nephropathy (IgAN)

Coming up8

Changes1

Last 90 days

Trials16

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 1 Dec 2026 A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
Phase 3Recruiting 31 May 2027 A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Phase 3Recruiting 28 Jan 2030 A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
Phase 3Enrolling by invitation 31 Dec 2031 A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)
Phase 2Recruiting 31 Jan 2028 A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
Phase 2Recruiting 10 Feb 2028 A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation
Phase 2Not yet recruiting 13 Aug 2028 A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN)
Phase 2Not yet recruiting 19 Sep 2028 A Study to Learn About the Effects of Felzartamab on Daily Living Activities and Its Safety in Adults With Generalized Myasthenia Gravis (gMG) Ages 18 to 80 Years Old
Phase 3Completed 30 Jun 2024 TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Phase 2Completed 28 Jan 2023 TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Phase 2Completed 6 Feb 2023 Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy
Phase 2Completed 14 Dec 2023 Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE)
Phase 1/2Completed 19 Jan 2022 Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)
Phase 1Terminated 14 Dec 2022 A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus
Phase 1Completed 24 Jun 2026 A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
Phase 2Ended not given Rescue Therapy with the Human Anti-CD38 Antibody MOR202 (felzartamab) in Patients with Membranous Nephropathy who Failed Anti-CD20 Target Therapy (MONET study)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Felzartamab

Following is part of Solo: you see every change to Felzartamab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in